Axim Biotechnologies Inc (OTCQB:AXIM)
| 0.70 Delayed Data As of Sep 18 |  +0.052 / +8.02%Today’s Change | 0.10 Today|||52-Week Range 1.44 | +91.78% Year-to-Date |
| SECTOR Industrial Services | INDUSTRY Environmental Services | MARKET CAP $82.8M |
Company Description
AXIM Biotechnologies, Inc. is a biotechnology company. It focuses in the research, development, and production of pharmaceutical, nutraceutical, cosmetic, and genetically controlled botanical products. The firm also involves in the extraction and purification of cannabinoids technologies based on its proprietary technologies. Its products include CBD-based controlled release chewing gum under CanChew brand; and a combination of CBD and THC gum that treats pain and spasticity associated with multiple sclerosis under MedChew Rx brand. The company was founded on November 18, 2010 and is headquartered in New York, NY.
Contact Information
AXIM Biotechnologies, Inc. 45 Rockefeller Plaza New York New York 10111 |
Employees
Shareholders
| Individual stakeholders | 34.40% |
| Mutual fund holders | -- |
| Other institutional | -- |
Top Executives
| John W. Huemoeller | Chief Executive Officer & Director |
| Robert T. Malasek | Chief Financial Officer & Secretary |
